Clinicians now have a tool to rapidly assess the efficacy of enoxaparin (Lovenox, Aventis) at the point-of-care. PharmaNetics, Morrisville, NC, recently launched the ENOX test card, which is used to detect the anticoagulant effects of enoxaparin, which is approved for seven indications, including the prophylaxis of ischemic complications of unstable angina and non-Q wave myocardial infarction. Enoxaparin is approved for more clinical indications than any other low-molecular weight heparin. PharmaNetics plans to launch its product during the first quarter of 2003.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.